Related Papers
Is Reporting of Recurrence Data Important in Pancreatic Cancer?
2004 •
John Hoffman
Therapeutic approaches to patients with pancreatic cancer have undergone a paradigm shift in recent years. However, little is known about the outcome of patients with recurrent pancreatic cancer who undergo treatment. The purpose of this study was to identify patients with recurrent pancreatic cancer and to determine whether treatment after recurrence had any effect on outcome. A review of all patients undergoing surgical resection with curative intent revealed 70 patients with documented recurrence and complete medical records. Patients were grouped into three categories: group 1 included those who received treatment after recurrence (n = 45), group 2 included those who were not offered treatment (n = 9), and group 3 included those with poor performance status who received no treatment (n = 16). The median overall survival for the three groups was 26, 18, and 14.5 months for groups 1, 2, and 3, respectively (P <.00001). The median survival after recurrence was 10 months, 6 months, and 1 month, respectively, for the three groups (P <.0001). This is the first series we are aware of that compares the outcomes of patients who received treatment after recurrence of pancreatic cancer with the outcomes of those who received no treatment. In this series, it seems that patients who were well enough to tolerate additional therapy had a longer survival than those who received supportive care only. This may be important in the analysis of adjuvant therapy trials of pancreatic cancer with survival as an end point.
Practitioner 255 21 3
Diagnosing and managing pancreatic cancer
2011 •
Matthew Huggett
British journal of cancer
Management and prognosis of pancreatic cancer over a 30-year period
2009 •
Marion Chauvenet, Côme Lepage
The aim of this study was to report on changes in the diagnostic assessment, patterns of care and survival over time for pancreatic cancers. A total of 2986 cases of pancreatic cancer from the Digestive Cancer Registry of Burgundy (France) over a 30-year period (1976-2005) were considered. Non-conditional logistic regressions were carried out to identify the factors associated with resection for cure and with the use of chemotherapy. A multivariate relative survival analysis was carried out. Diagnostic procedures have changed. Ultrasonography and computed tomography progressively have become the major diagnostic procedures. There was a slight improvement in stage: the proportion of stage I-II was 2.8% in the 1976-1980 period and 8.8% in the 2001-2005 period (P<0.001). There was a similar trend in the proportion of cases resected for cure, the corresponding percentages being 4.5 and 11.3%, respectively (P<0.001). The 5-year relative survival increased from 2.0 to 4.2% (P<0.0...
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy
Pancreatic Cancer: Alarm for Survival
Marcellus Simadibrata
Pancreatic cancer is one of the deadliest and a highly aggressive cancer. Its incidence and mortality are highest in developed countries. However, in Asia-Pacific region, the incidence and mortality rate of pancreatic cancer are also on increasing trend nowadays. Pancreatic cancer incidence rates increase with older age, the highest in the 7th and 8th decades. Clinical presentation of pancreatic cancer are usually non-specific, largely dependent on tumour size and location, with most patients experience symptoms already late in the disease. Computed tomography is considered the method of choice for diagnosis and staging of pancreatic cancer. Management for pancreatic cancer include surgical resection, radiotherapy, chemotherapy. Only surgical resection considered the potentially curative treatment for pancreatic cancer. Unfortunately, a lot of patients present with disease that is not surgically resectable. Prognosis for pancreatic cancer is very poor, despite surgery in resectable...
Annals of Oncology
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006
2007 •
Josep Tabernero, P. Johnston
Canadian Medical Association Journal
Diagnosis and management of pancreatic cancer
2013 •
Lesley Goodburn
Cancer Medicine
Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis
Yunes Doleh
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
2016 •
Alfredo Carrato
The management of patients with pancreatic cancer has advanced over the last few years. We convey a multidisciplinary group of experts in an attempt to stablish practical guidelines for the diagnoses, staging and management of these patients. This paper summarizes the main conclusions of the working group. Patients with suspected pancreatic ductal adenocarcinoma should be rapidly evaluated and referred to high-volume centers. Multidisciplinary supervision is critical for proper diagnoses, staging and to frame a treatment plan. Surgical resection together with chemotherapy offers the highest chance for cure in early stage disease. Patients with advanced disease should be classified in treatment groups to guide systemic treatment. New chemotherapeutic regimens have resulted in improved survival. Symptomatic management is critical in this disease. Enrollment in a clinical trial is, in general, recommended.
Cancers
Management and Outcomes of Pancreatic Cancer in French Real-World Clinical Practice
Côme Lepage
Background: Our objective was to describe real-world patterns of care and outcomes in pancreatic cancer. Methods: 912 patients diagnosed with pancreatic cancer from 2014 to 2017 were registered by the population-based cancer registry of Burgundy (France). Progression-free and net survival were estimated. Results: at diagnosis, 52% of tumors were associated with metastases. Among the 20% of patients fulfilling resectability criteria, half of those aged 75–84 years and none of those ≥85 years actually underwent resection. Age was not associated with 3-year observed survival in patients who underwent resection. Overall, 77% of patients aged <75 years, 55% of those aged 75–84 years and 8% of those ≥85 years received chemotherapy. Among patients who were offered chemotherapy, 73% of those aged ≥85 years refused. Chemotherapy toxicity was higher with Gemcitabine_Oxaliplatin/Gemcitabine_Abraxane and FOLFIRINOX than with Gemcitabine alone. Patients resected after induction FOLFIRINOX and...
CA: A Cancer Journal for Clinicians
Recent progress in pancreatic cancer
2013 •
Christopher Wolfgang
